Hutchinson-Gilford progeria syndrome complicated with stroke: A report of 2 cases and literature review

Introduction

Hutchinson–Gilford progeria syndrome (HGPS) is a ultrarare fatal syndrome of segmental premature aging that begins in the early childhood. It has an estimated overall incidence rate of 1 in 4–8 million newborns (1). HGPS arises from a sporadic autosomal dominant mutation in LMNA, which produces an aberrant form of the inner nuclear membrane protein lamin A known as progerin. Progerin is expressed in differentiated cell types, including vascular smooth muscle cells, endothelial cells, and adventitial fibroblasts, which are integral to the vascular structure and function. HGPS is manifested as growth retardation, a gradual progression of characteristic facial features, the loss of hair and subcutaneous fat, restricted joint mobility, and rapidly progressing severe atherosclerosis. Children with HGPS appear superficially normal at birth, but they start developing substantial growth delays within the first year of life. Subsequently, their symptoms worsen with time. The afflicted children have a median life expectancy of 14.6 years (2), and the most common causes of death are cardiovascular complications such as stroke or myocardial infarction. Despite the extremely low prevalence of stroke in HGPS, little is known about the nature of strokes and the vascular characteristics of the head of these patients. Herein we have reported the cases of two HGPS patients who experienced strokes. This study analyzed the clinical and imaging characteristics of HGPS children with stroke in conjunction with the relevant literature review to improve the pediatricians’ knowledge of this disease.

Case presentation

Case 1

A 4-year-old boy patient was admitted to the hospital with the chief complaint of “hard skin for more than 3 years, unclear vision, and communication obstacle for a day” with no family history of HGPS. The boy appeared normal at birth, weighing 3 kg, but he soon failed to thrive. After 1 month of birth, his skin appeared swollen and sclerodermatous on the trunk, with the loss of scalp hair along with stunted growth. Before his admission, the child experienced blurred vision, followed by communication difficulties, dull eyes, and an inability to speak and communicate.

On examination, the child showed distinctive facial features, with prominent eyes and scalp veins, delayed closure of the anterior fontanelle, generalized alopecia with sparse downy hairs, narrow nasal bridge, thin lips, micrognathia, and small ear lobes (Figure 1A). His neck is soft, Brinell's sign is negative, Klinefelter's sign is negative, Babbitt's sign is positive on both sides, tendon reflexes are present, limb muscle strength is grade IV, muscle tension is high , and the skin on the entire body is stiff with poor elasticity, and a lot of mottled pigmentation is present on the trunk (Figure 1B). Bilateral metacarpophalangeal joint contracture deformity (Figure 1C), lexion deformity of both the proximal knuckles, squatting difficulty, and hip and knee joint contractures were fixed, and a horse-riding posture was detected. He was 77 cm tall (<1st percentile) and weighed 7.8 kg (<1st percentile). He could not pronounce and communicate, and he was too young to receive detailed ophthalmic examination.

FIGURE 1

Figure 1. A 4-year-old boy patient. (A) The child has severe growth retardation; he showed distinctive facial features, scalp veins, generalized alopecia with sparse downy hairs, narrow nasal bridge, thin lips, and micrognathia. (B) Dry and stiff skin on the entire body, poor elasticity, and a lot of mottled pigmentation on the trunk. (C) Flexion deformity of the proximal phalangeal joints of both the fingers. (D) The shape of the head is enlarged, the anterior fontanelle and cranial suture are not closed, and the cranial plate of the parietal occipital region is thinned. (E) Multiple deformities of the ribs on both sides, dysplasia of the clavicle and scapula on both sides. (F) Cranial MRI at the time of onset: Multiple abnormal signals around the lateral ventricle. (G) Cranial MRA at the time of onset: The red arrow indicates bilateral internal carotid artery stenosis. (H) After the 3-month review, Cranial MRI: bilateral paraventricular lacunar infarction. (I) After the 3-month review, Cranial MRA: The red arrow indicates bilateral internal carotid artery stenosis similar to that noted earlier.

The complete blood count, liver and renal function tests, cardiac enzymes, serum electrolytes, and lipids were within the normal limits. An electrocardiogram and ultrasonic cardiogram revealed no anomalies. His radiographic examination revealed general osteoporotic changes, with short and dystrophic clavicles and distal phalanges osteolysis. His lateral skull X-ray revealed cranial dysplasia (Figure 1D). Chest X-ray showed bilateral clavicle dysplasia and bilateral rib deformity (Figure 1E). Carotid artery B-ultrasound revealed 0.05 cm intima-media thickening in both common carotid arteries. EEG revealed moderate abnormalities, with more irregular delta waves. Brain MRI revealed multiple abnormal signals in the bilateral frontoparietal cortex, bilateral semiovale center, and lateral ventricle, as well as multiple abnormal signals in the deep frontoparietal white matter, suggesting cerebral infarction (Figure 1F). His cranial MRA revealed bilateral internal carotid artery stenosis with basilar artery and thickening of the bilateral posterior communicating artery (Figure 1G). A re-examination of his head MRI after 3 months revealed bilateral paraventricular and central semiovale lacunar infarction (Figure 1H). A re-examination after 3 months of head MRA bilateral internal carotid artery was similar to the previous one (Figure 1I). The patient's history and examination findings supported the diagnosis of HGPS. DNA sequence analysis was performed to confirm the clinical diagnosis. The patient carried a c.1824C > T (p.G608G) heterozygous LMNA mutation.

There is no specific treatment plan for this child. After admission, cerebroside carnosine was used to protect the brain, nimodipine to dilate the blood vessels, low molecular weight heparin combined with aspirin for anticoagulation, low molecular weight dextran to improve circulation, and mannitol to reduce intracranial pressure.

The patient's consciousness improved after treatment and he was discharged from the hospital, with a 1-month follow-up scheduled at the neurology department. The child was conscious, could pronounce and communicate normally, and could walk on his own. Three months after discharge from the hospital, his head MRI revealed bilateral paraventricular and central semiovale lacunar infarction, while his head MRA showed bilateral internal carotid artery stenosis.

Case 2

The second case is an 8.5-year-old boy who was born at term through cesarean section owing to “low fetal movement and cloudy amniotic fluid”. His birth weight was 3.1 kg, and he had a normal family history. He was admitted to our hospital for “sclerosis of the skin for more than 8 years, decreased muscle strength of the right limb, choking on drinking water for 3 days, and vomiting for a day”. Similar to Case 1, the child developed progressive skin sclerosis approximately 20 days after delivery, after which he gradually developed hair loss, misaligned teeth, and joint deformities, accompanied by severe growth retardation. Notably, the child developed recurrent paroxysmal headaches at the age of 3 years, with no obvious abnormality in the head MRI; as a result, no treatment was prescribed at this time. Three months before his admission, the child developed severe headache that improved after oral administration of aspirin. Three days before his admission, he developed weakness in his right upper extremity and choked easily on drinking water, followed by vomiting.

Physical examination: Similar to case 1, there is progeria appearance, which is manifested as a prominent forehead, baldness, exposed scalp veins, long and narrow nose, thin upper lip, micrognathia, and irregular dentition (Figure 2A). Neurological examination showed a soft neck, a negative Brucella sign, a negative Klinefelter sign, a positive bilateral Barthel sign, tendon reflexes, and right upper extremity muscle strength grade IV. The child exhibited flexion deformity of the distal knuckle joints of both the fingers (Figure 2B), abduction of the bilateral wrist and hip joints, flexion of the bilateral wrist and ankle joints, and anteversion of the spine. The child has a stiff, dry, and poorly elastic, with a lot of mottled pigmentation on the torso.

FIGURE 2

Figure 2. An 8.5-year-old boy patient. (A) The child showed distinctive facial features, with prominent forehead, baldness, exposed scalp veins, long and narrow nose, thin upper lip, and micrognathia. (B) The child exhibited flexion deformity of the distal knuckle joints of both the fingers, abduction of the bilateral wrist. (C) Anteroposterior pelvis X-ray showed bilateral hip dysplasia, bilateral femoral heads laterally positioned and left femoral head aseptic necrosis. (D) Long bones with thin diaphysis, widened metaphysis, and decreased bone density. (E) Cranial MRI at the time of onset: multiple abnormal signal shadows in the lateral ventricle. (F) Cranial MRA at the time of onset: bilateral internal carotid artery stenosis. The red arrow indicates internal carotid artery stenosis, and the yellow arrow indicates left anterior cerebral artery stenosis. (G) After the 3-month review, cranial MRI: multiple abnormal signal shadows in the lateral ventricle, and the left basal Nodal lesions. (H) After the 3-month review, cranial MRA: his left internal carotid artery, left middle cerebral artery and left cerebral artery had stenosis. The red arrow indicates internal carotid artery stenosis, the blue arrow indicates left middle cerebral artery stenosis, and the yellow arrow indicates left anterior cerebral artery stenosis.

His complete blood count, liver and renal function tests, cardiac enzymes, serum electrolytes, and lipids were within normal limits. An electrocardiogram and ultrasonic cardiogram revealed no anomalies. Chest X-ray showed bilateral clavicle dysplasia and bilateral rib deformity; anteroposterior pelvis X-ray showed bilateral hip dysplasia, bilateral femoral heads laterally positioned and left femoral head aseptic necrosis (Figure 2C); and the long bones of his limbs were thin and dry (Figure 2D). The epiphysis was relatively wide, and the bilateral elbow angle was negative (cubitus varus); the lateral X-ray of the skull revealed cranial dysplasia. Carotid artery B-ultrasound showed that the bilateral carotid intima was slightly thickened (about 0.1 cm), and the bilateral internal carotid lumen was locally narrowed. The EEG was normal, and his head MRI revealed that the bilateral frontal lobes were small, with multiple abnormal signal shadows in the bilateral center of the semiovale and the lateral ventricle (Figure 2E). His brain MRA indicated that the bilateral internal carotid arteries (C5–7) were narrow and uneven in thickness, and the A1 segment of the left anterior cerebral artery was narrower than the contralateral one (Figure 2F). After the 3-month review, his head MRI revealed multiple abnormal signal shadows in the two cerebral hemispheres indicating an ischemic foci, the left basal Nodal lesions, and cerebral infarction to be discharged (Figure 2G). At re-examination after 3 months, his brain MRA revealed stenosis of his left internal carotid artery, left middle cerebral artery and left cerebral artery (Figure 2H). The proximal anterior artery was narrowed as was the right internal carotid artery. Genetic testing revealed a de novo heterozygous mutation in the chromosome 1 LMNA (c.1824C > T (p.G608G)). After admission, he was administered enalapril maleate, valsartan, amlodipine besylate to lower blood pressure, cerebroside carnosine to protect the brain, nimodipine to dilate the blood vessels, and low molecular weight heparin mixed with aspirin for anticoagulation. He was treated with glycosides to improve circulation and mannitol to lower the intracranial pressure before discharge from the hospital. After discharging from the hospital, his rehabilitation training was continued. After 2 months later, the muscle strength of his right upper extremity basically returned to normal and he no longer choked after drinking water.

Discussion

HGPS is a ultrarare, fatal, premature aging syndrome. Most HGPS infants appear healthy at birth, but they begin to exhibit aging features within the first year of life (3). The most common early symptoms of HGPS are skin tightness or bulge in the abdomen and/or thigh area, while the other symptoms include growth retardation, loss of body fat, and hair loss skin changes (4), hip dislocation (5), generalized atherosclerosis, cardiovascular disease, and stroke. However, most intellectual development is normal, unless there is a sequelae caused by stroke (6). With an average age of 14.6 years, the most common causes of death among children with HGPS are cardiovascular complications such as stroke or myocardial infarction. Individuals with classic genotype HGPS are heterozygous for pathogenic variant c.1824C > T (∼90% of individuals with HGPS). The LMNA c.1824C > T mutation results in the activation of a cryptic donor splice site leading to the production of a lamin A isoform, called progerin, which contains an internal deletion of 50 amino acids near its C-terminal end. This deletion eliminates the site for endo-proteolytic cleavage by ZMPSTE24, a zinc metalloproteinase that cleaves the 15 C-terminal amino acids of prelamin A to yield mature lamin A. Therefore, progerin retains its farnesyl moiety at the C-terminus. Retention of the farnesyl group causes progerin to become permanently anchored into the nuclear membrane, leading to a whole variety of abnormalities in the nuclear processes, which eventually lead to cellular and organismal decline (7). Individuals with nonclassical genotype HGPS show the characteristic clinical features of HGPS and are heterozygous for another LMNA pathogenic variant in exon 11 or intron 11, which results in the production of progerin (∼10% of individuals with HGPS) (8, 9). Until now, a total of 11 LMNA pathogenic variant in the nonclassical genotype HGPS have been identified, and their clinical phenotypes vary in severity (see details in Table 1).

TABLE 1

Table 1. Genotypes of HGPS, Causative LMNA Variants and Clinical Phenotypes.

The two case reports discussed in this study showed no obvious abnormalities at birth, and both started developing progressive hardening of the skin around 1 month after birth, along with severe growth retardation, hair loss, irregular teeth, joint deformities, and other typical premature aging symptoms. Both the children are classic genotype HGPS. Children usually have a lower stroke incidence than adults, and the most common risk factors include infection and trauma (10). For children with HGPS, progerin produced by LMNA mutation is deposited in the blood vessels, causing premature aging and disappearance of smooth muscle cells, resulting in fibrosis, atheromatous changes, and hardening of the blood vessels (11), especially those of the head and neck. To compensate, the blood vessels form the auxiliary vessels or “bypasses,” to aid the blood flow and supply oxygen to the areas of the brain that were previously served by narrowed arteries. However, these new blood vessels are smaller and more fragile than normal blood vessels, which increases the risk of stroke. The patients in this study showed no symptoms of infection such as fever, cough, diarrhea, and no clear history of trauma; therefore, the stroke was considered to result from the primary disease.

Cerebrovascular events can occur in children with HGPS at any age. The first symptom is usually stroke or transient ischemic attack, which seriously affects the quality of life in children. The earliest report in the literature shows the age of occurrence of 4 years, which is similar to that of case 1 in this report. The symptoms are also comparable with those associated with other secondary causes of stroke in children, such as embolism and cerebrovascular malformation (12). We have summarized the clinical symptoms of children with HGPS complicated with stroke, indicating hemiplegia and physical weakness as the most prevalent stroke symptoms in children with HGPS, followed by headache, epilepsy, dysarthria, and psychosis as the primary manifestation in some children (Table 2). In this study, case 1 had a sudden blurred vision as the primary symptom, followed by communication disorder, dull eyes, inability to speak and communicate, and no other neurological symptoms such as hemiplegia and epilepsy. Case 2 was mainly manifested by decreased muscle strength of the right limb and choking after drinking water. Unlike for case 1, this child had a history of recurring headaches before the stroke. In addition, among the 10 cases we have counted, 1 child showed no symptoms at the time of cerebral infarction. However, according to Silvera et al, more than half of the HGPS children with clear imaging evidence of cerebral infarction do not have evident clinical symptoms (13). As a result, even in the absence of neurological symptoms, the children must be closely monitored with brain MRI and head and neck MRA examinations to determine the existence and severity of the intracranial diseases.

TABLE 2

Table 2. Related reports of HGP children with stroke.

In this study, we collected relevant reports on HGPS children with stroke over the years. The results showed that most strokes in children with HGPS are ischemic cerebral infarction caused by the insufficient cerebral blood supply. However, children can die from cerebral hemorrhage secondary to ischemic cerebral infarction. In children, the main cerebral infarction occurs in the field of large blood vessels, which involves all vascular regions, and mostly affects the internal carotid artery, anterior and middle cerebral arteries, and posterior artery stenosis is rare (Table 2). Children with HGPS often suffer from chronic brain hypoperfusion, which can easily cause ischemic damage to the cerebral white matter. Confluent white matter lesions in the cerebral hemisphere are also common (14). Multiple abnormal signals were seen in the bilateral frontoparietal cortex and around the lateral ventricle in Case 1, along with multiple abnormal signals in the deep frontal and parietal white matter. In Case 2, multiple abnormal signal shadows appeared in the child's bilateral cerebral hemispheres, all of which had such characteristics.

There is currently no specific treatment for HGPS. The main treatment is to relieve symptoms and control secondary organ dysfunction. Lonafanib, an orally active farnesyl protein transferase (FPTase) inhibitor, has been approved by the US FDA for the treatment of HGPS and some specific progeroid laminopathy. It can effectively reduce the possibility of heart disease and stroke in children with HGPS and prolong the life of HGPS children, but it cannot reverse and prevent the progression of the disease (15). Moreover, it is very expensive and has not been on market in China.

Treatment of atherosclerosis, stroke and other complications is achieved through standard conventional monitoring and medical therapy, but the disorder will continue to progress. Low-dose aspirin is currently recommended for preventing heart disease and stroke in children with HGPS. Moreover, since hardened vascular systems are more susceptible to dehydration, oral intake is recommended for optimal hydration. Appropriate physical activity is also encouraged to minimize stroke risk. Once a child is suspected of having a stroke, symptomatic and supportive care should be given as soon as possible: 1) oxygen supplementation and fluid infusion should be applied to improve their vascular status; 2) anticoagulants other than the routinely recommended aspirin may be warranted, such as low molecular weight heparin, warfarin, rivaroxaban and others (9); 3) controlling blood pressure and epileptic seizures is also important to reduce reversible and irreversible brain damage due to cerebral infarction. In this study, both children administered cerebroside carnosine to protect the brain, nimodipine to dilate the blood vessels, low molecular weight heparin mixed with aspirin for anticoagulation, glycosides to improve circulation and mannitol to lower the intracranial pressure. After treatment, the symptoms of the two children improved significantly.

Interestingly, the brain MRI features of these HGPS children with stroke resemble early stages of moyamoya vasculopathy which is also a steno-occlusive disease of the cerebral arteries, so in addition to antiplatelet, revascularization is a potential preventive approach (16, 17). However, due to the poor prognosis of HGPS, revascularization was not an option for stroke prevention in either case. There is no report on thrombolysis or revascularization in children with HGPS complicated with cerebral infarction.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author/s.

Ethics statement

The studies involving human participants were reviewed and approved by Medical Ethics Committee of Children's Hospital affiliated to Zhejiang University School of Medicine. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minor(s)' legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author contributions

JJW and QY: designed the study, drafted the initial manuscript, and reviewed and revised the manuscript. XHM and ZFY: analyzed and interpreted clinical and imaging data. JM: designed the study, coordinated, and supervised data collection, and critically reviewed the manuscript for important intellectual content. All authors contributed to the article and approved the submitted version.

Acknowledgments

We thank the patient and their family for their participation, we are particularly grateful to the CORD organization and the Zhejiang Sunflower Foundation for their support.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A. (2006) 140(23):2603–24. doi: 10.1002/ajmg.a.31346

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Gordon LB, Massaro J, D’Agostino RB Sr, Campbell SE, Brazier J, Brown WT, et al.. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. (2014) 130(1):27–34. doi: 10.1161/circulationaha.113.008285

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, et al.. Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics. (2007) 120(4):824–33. doi: 10.1542/peds.2007-1357

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, et al.. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. (2008) 358(6):592–604. doi: 10.1056/NEJMoa0706898

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Rork JF, Huang JT, Gordon LB, Kleinman M, Kieran MW, Liang MG. Initial cutaneous manifestations of Hutchinson-Gilford progeria syndrome. Pediatr Dermatol. (2014) 31(2):196–202. doi: 10.1111/pde.12284

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Kieran MW, Gordon L, Kleinman M. New approaches to progeria. Pediatrics. (2007) 120(4):834–41. doi: 10.1542/peds.2007-1356

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Marcelot A, Worman HJ, Zinn-Justin S. Protein Structural and Mechanistic Basis of Progeroid Laminopathies. Febs j (2021) 288(9):2757–72. Epub 20200903. doi: 10.1111/febs.15526

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al.. Recurrent De Novo point mutations in lamin a cause Hutchinson-Gilford progeria syndrome. Nature. (2003) 423(6937):293–8. doi: 10.1038/nature01629

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Gordon LB, Brown WT, Collins FS. Hutchinson-Gilford Progeria Syndrome. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., Genereviews(®). Seattle (WA): University of Washington, Seattle Copyright 1993–2022, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. (1993).

10. Naoemova I, De Wachter S, Wuyts FL, Wyndaele JJ. Reliability of the 24-H Sensation-Related Bladder Diary in Women with Urinary Incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2008) 19(7):955–9. doi: 10.1007/s00192-008-0565-3.18235981

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Hamczyk MR, Andrés V. Vascular Smooth Muscle Cell Loss Underpins the Accelerated Atherosclerosis in Hutchinson-Gilford Progeria Syndrome. Nucleus (2019) 10(1):28–34. doi: 10.1080/19491034.2019.1589359.30900948

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Tsze DS, Valente JH. Pediatric Stroke: A Review. Emerg Med Int (2011) 2011:734506. Epub 20111227. doi: 10.1155/2011/734506.22254140

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ. Imaging Characteristics of Cerebrovascular Arteriopathy and Stroke in Hutchinson-Gilford Progeria Syndrome. AJNR Am J Neuroradiol (2013) 34(5):1091–7. Epub 20121122. doi: 10.3174/ajnr.A3341.23179651

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. (1997) 28(3):652–9. doi: 10.1161/01.str.28.3.652

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Gordon LB, Shappell H, Massaro J, D'Agostino RB Sr, Brazier J, Campbell SE, et al.. Association of Lonafarnib Treatment Vs No Treatment with Mortality Rate in Patients with Hutchinson-Gilford Progeria Syndrome. Jama (2018) 319(16):1687–95. doi: 10.1001/jama.2018.3264.29710166

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Ihara M, Yamamoto Y, Hattori Y, Liu W, Kobayashi H, Ishiyama H, et al.. Moyamoya Disease: Diagnosis and Interventions. Lancet Neurol (2022) 21(8):747–58. Epub 20220520. doi: 10.1016/s1474-4422(22)00165-x.35605621

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Scala M, Fiaschi P, Capra V, Garrè ML, Tortora D, Ravegnani M, et al.. When and Why Is Surgical Revascularization Indicated for the Treatment of Moyamoya Syndrome in Patients with Rasopathies? A Systematic Review of the Literature and a Single Institute Experience. Childs Nerv Syst (2018) 34(7):1311–23. Epub 20180524. doi: 10.1007/s00381-018-3833-7.29797062

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Reunert J, Wentzell R, Walter M, Jakubiczka S, Zenker M, Brune T, et al.. Neonatal Progeria: Increased Ratio of Progerin to Lamin a Leads to Progeria of the Newborn. European journal of human genetics : EJHG (2012) 20(9):933–7. Epub 2012/03/16. doi: 10.1038/ejhg.2012.36.22419169

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Fukuchi K, Katsuya T, Sugimoto K, Kuremura M, Kim HD, Li L, et al.. Lmna Mutation in a 45 Year Old Japanese Subject with Hutchinson-Gilford Progeria Syndrome. Journal of medical genetics (2004) 41(5):e67. Epub 2004/05/04. doi: 10.1136/jmg.2003.014688.15121795

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Wang Y, Lichter-Konecki U, Anyane-Yeboa K, Shaw JE, Lu JT, Östlund C, et al.. A Mutation Abolishing the Zmpste24 Cleavage Site in Prelamin a Causes a Progeroid Disorder. (2016) 129(10):1975–80. doi: 10.1242/jcs.187302.

CrossRef Full Text | Google Scholar

21. Hisama FM, Lessel D, Leistritz D, Friedrich K, McBride KL, Pastore MT, et al.. Coronary Artery Disease in a Werner Syndrome-Like Form of Progeria Characterized by Low Levels of Progerin, a Splice Variant of Lamin A. American journal of medical genetics Part A (2011) 155a(12):3002–6. Epub 2011/11/09. doi: 10.1002/ajmg.a.34336.22065502

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Moulson CL, Fong LG, Gardner JM, Farber EA, Go G, Passariello A, et al.. Increased Progerin Expression Associated with Unusual Lmna Mutations Causes Severe Progeroid Syndromes. Human mutation (2007) 28(9):882–9. Epub 2007/05/01. doi: 10.1002/humu.20536.17469202

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Bar DZ, Arlt MF, Brazier JF, Norris WE, Campbell SE, Chines P, et al.. A Novel Somatic Mutation Achieves Partial Rescue in a Child with Hutchinson-Gilford Progeria Syndrome. Journal of medical genetics (2017) 54(3):212–6. Epub 2016/12/07. doi: 10.1136/jmedgenet-2016-104295.27920058

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Alghamdi SA. A Case of Progeria in a Saudi Child Presenting with Cerebral Infarction. Ann Saudi Med (1995) 15(6):631–3. doi: 10.5144/0256-4947.1995.631.17589026

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Tannock TC, Cook RF. A Case of a Delusional Psychotic Syndrome in the Setting of Werner's Syndrome (Adult Progeria). Br J Psychiatry (1988) 152:703–4. doi: 10.1192/bjp.152.5.703.3167450

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Wagle WA, Haller JS, Cousins JP. Cerebral Infarction in Progeria. Pediatr Neurol (1992) 8(6):476–7. doi: 10.1016/0887-8994(92)90014-p.1476581

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Rosman NP, Anselm I, Bhadelia RA. Progressive Intracranial Vascular Disease with Strokes and Seizures in a Boy with Progeria. J Child Neurol (2001) 16(3):212–5. doi: 10.1177/088307380101600309.11305689

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Smith AS, Wiznitzer M, Karaman BA, Horwitz SJ, Lanzieri CF. Mra Detection of Vascular Occlusion in a Child with Progeria. AJNR Am J Neuroradiol. (1993) 14(2):441–38456725

PubMed Abstract | Google Scholar

29. Narazaki R, Makimura M, Sanefuji M, Fukamachi S, Akiyoshi H, So H, et al.. Bilateral Stenosis of Carotid Siphon in Hutchinson-Gilford Progeria Syndrome. Brain Dev. (2013) 35(7):690–3. Epub 20121108. doi: 10.1016/j.braindev.2012.10.008

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Matsuo S, Takeuchi Y, Hayashi S, Kinugasa A, Sawada T. Patient with Unusual Hutchinson-Gilford Syndrome (Progeria). Pediatr Neurol. (1994) 10(3):237–40. doi: 10.1016/0887-8994(94)90030-2

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Toni L, Dušátková P, Novotná D, Zemková D, Pruhová Š, Lebl J. Short Stature in a Boy with Atypical Progeria Syndrome Due to Lmna C.433ga>a [P.(Glu145lys)]: Apparent Growth Hormone Deficiency but Poor Response to Growth Hormone Therapy. J Pediatr Endocrinol Metab. (2019) 32(7):775–9. doi: 10.1515/jpem-2019-0107

PubMed Abstract | CrossRef Full Text | Google Scholar